دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Multidimensional Impact of Mediterranean Diet on IBD Patients
Fabio Chicco, MD, Salvatore Magr?, MD, Arianna Cingolani, MD, Danilo Paduano, MD, Mario Pesenti, MD ...
doi : 10.1093/ibd/izaa097
Inflammatory Bowel Diseases, Volume 27, Issue 1, January 2021, Pages 1–9
Malnutrition with the accumulation of fat tissue and nonalcoholic fatty liver disease (NAFLD) are conditions associated with inflammatory bowel disease (IBD). Visceral fat and NAFLD-related liver dysfunction can both worsen intestinal inflammation. Because the Mediterranean diet (Md) has been shown to ameliorate both obesity and NAFLD, the aim of this study was to analyze the impact of Md on the nutritional state, liver steatosis, clinical disease activity, and quality of life (QoL) in IBD patients.
Implications of Dietary Impact on Hepatic Steatosis and IBD
Yejoo Jeon, MD, Berkeley N Limketkai, MD, PhD
doi : 10.1093/ibd/izaa098
Inflammatory Bowel Diseases, Volume 27, Issue 1, January 2021, Pages 10–11
Bacterial Mucosa-associated Microbiome in Inflamed and Proximal Noninflamed Ileum of Patients With Crohn’s Disease
Maya Olaisen, MD, Arnar Flatberg, PhD, Atle van Beelen Granlund, PhD, Elin Synn?ve R?yset, MD, Tom Christian Martinsen, MD, PhD ...
doi : 10.1093/ibd/izaa107
Inflammatory Bowel Diseases, Volume 27, Issue 1, January 2021, Pages 12–24
Microbiota is most likely essential in the pathogenesis of Crohn’s disease (CD). Fecal diversion after ileocecal resection (ICR) protects against CD recurrence, whereas infusion of fecal content triggers inflammation. After ICR, the majority of patients experience endoscopic recurrence in the neoterminal ileum, and the ileal microbiome is of particular interest. We have assessed the mucosa-associated microbiome in the inflamed and noninflamed ileum in patients with CD.
Incidence, Clinical Characteristics, and Evolution of SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: A Single-Center Study in Madrid, Spain
Ivan Guerra, MD, PhD, Alicia Algaba, MSc, PhD, Laura Jiménez, MSc, M? Mar Aller, RN, Daniel Garza, RN ...
doi : 10.1093/ibd/izaa221
Inflammatory Bowel Diseases, Volume 27, Issue 1, January 2021, Pages 25–33
There are scarce data about SARS-CoV-2 infection in patients with inflammatory bowel disease (IBD). Our aim was to analyze the incidence, clinical presentation, and severity of SARS-CoV-2 infection in patients with IBD.
The Incidence and Prevalence of Human Papilloma Virus–associated Cancers in IBD
Jonathan P Segal, PhD, Alan Askari, PhD, Susan K Clark, MD, Ailsa L Hart, PhD, Omar D Faiz, MD
doi : 10.1093/ibd/izaa035
Inflammatory Bowel Diseases, Volume 27, Issue 1, January 2021, Pages 34–39
The human papilloma virus has been associated with anal, cervical, vaginal, and penile cancers. The primary aim of this population-based study is to determine whether HPV-associated cancers are more commonplace in patients with inflammatory bowel disease (IBD).
Mental Health Costs of Inflammatory Bowel Diseases
Eva Szigethy, MD, PhD, Sean M Murphy, PhD, Orna G Ehrlich, MPH, Nicole M Engel-Nitz, PhD, Caren A Heller, MD, MBA ...
doi : 10.1093/ibd/izaa030
Inflammatory Bowel Diseases, Volume 27, Issue 1, January 2021, Pages 40–48
Mental health diagnoses (MHDs) were identified as significant drivers of inflammatory bowel disease (IBD)-related costs in an analysis titled “Cost of Care Initiative” supported by the Crohn’s & Colitis Foundation. In this subanalysis, we sought to characterize and compare IBD patients with and without MHDs based on insurance claims data in terms of demographic traits, medical utilization, and annualized costs of care.
Transition Readiness Not Associated With Measures of Health in Youth With IBD
Marina Arvanitis, MD, MPH, Laura C Hart, MD, MPH, Darren A DeWalt, MD, MPH, Maria E D?az-Gonz?lez de Ferris, MD, MPH, PhD, Gregory S Sawicki, MD, MPH ...
doi : 10.1093/ibd/izaa026
Inflammatory Bowel Diseases, Volume 27, Issue 1, January 2021, Pages 49–57
It remains unclear how transition readiness is associated with various domains of health in children and young adults. Our objective was to describe the transition readiness of children and young adults with inflammatory bowel disease (IBD) and examine its associations with demographic factors, IBD activity, and measures of physical, psychological, and social health.
Prevalence and Risk Factors of Substance Use Disorder in Inflammatory Bowel Disease
Heather Carney, Ruth Ann Marrie, MD, PhD, James M Bolton, MD, Scott B Patten, MD, PhD, Lesley A Graff, PhD ...
doi : 10.1093/ibd/izaa014
Inflammatory Bowel Diseases, Volume 27, Issue 1, January 2021, Pages 58–64
Substance use disorders (SUDs) impose a substantial individual and societal burden; however, the prevalence and associated factors in persons with inflammatory bowel disease (IBD) are largely unknown. We evaluated the prevalence and risk factors of SUD in an IBD cohort.
Dietary Patterns, Ultra-processed Food, and the Risk of Inflammatory Bowel Diseases in the NutriNet-Santé Cohort
Pauline Vasseur, MPH, Emmanuelle Dugelay, MD, Robert Benamouzig, MD, PhD, Guillaume Savoye, MD, PhD, Annaïg Lan, PhD ...
doi : 10.1093/ibd/izaa018
Inflammatory Bowel Diseases, Volume 27, Issue 1, January 2021, Pages 65–73
The incidence of inflammatory bowel diseases (IBDs) tended to increase for several decades. Diet is suspected to be a major determinant of the occurrence of these diseases. This prospective study aimed to assess the associations among occurrence of IBD, dietary patterns, and ultra-processed food in the French NutriNet-Santé cohort.
Retinoic Acid Is Elevated in the Mucosa of Patients With Active Ulcerative Colitis and Displays a Proinflammatory Role by Augmenting IL-17 and IFN? Production
Ritika Rampal, PhD, Nahidul Wari, PhD, Amit Kumar Singh, MSc, Ujjwalkumar Das, PhD, Sawan Bopanna, DM ...
doi : 10.1093/ibd/izaa121
Inflammatory Bowel Diseases, Volume 27, Issue 1, January 2021, Pages 74–83
All-trans retinoic acid (RA) plays a crucial role in promoting Foxp3+ Treg generation while reciprocally inhibiting Th1/Th17 generation. Our previous research highlighted that in the face of inflammatory conditions, RA plays a contrary role where it aggravates intestinal inflammation by promoting interferon (IFN) ? and interleukin (IL)-17 differentiation in vitro.
IL-37d Negatively Regulates NLRP3 Transcription via Receptor-mediated Pathway and Alleviates DSS-induced Colitis
Yuan Li, PhD, Hongxia Chu, MS, Mingsheng Zhao, PhD, Chaoze Li, BS, Yetong Guan, BS ...
doi : 10.1093/ibd/izaa124
Inflammatory Bowel Diseases, Volume 27, Issue 1, January 2021, Pages 84–93
Interleukin-37 (IL-37) is a new negative immune regulator. It has 5 splicing forms, IL-37a–e, and most research mainly focuses on IL-37b functions in diverse diseases. Our previous research found that IL-37d inhibits lipopolysaccharide-induced inflammation in endotoxemia through a mechanism different from that of IL-37b. However, whether IL-37d plays a role in colitis and the underlying mechanisms is still obscure. Herein, we identified whether IL-37d regulates NLRP3 inflammasome activity and determined its effect on colitis.
Transcriptional Signatures That Define Ulcerative Colitis in Remission
Christopher G Fenton, PhD, Hagar Taman, MSc, Jon Florholmen, MD, PhD, Sveinung W S?rbye, MD, PhD, Ruth H Paulssen, PhD
doi : 10.1093/ibd/izaa075
Inflammatory Bowel Diseases, Volume 27, Issue 1, January 2021, Pages 94–105
This study addresses whether existing specific transcriptional profiles can improve and support the current status of the definition of ulcerative colitis (UC) remission apart from the existing endoscopic, histologic, and laboratory scoring systems. For that purpose, a well-stratified UC patient population in remission was compared to active UC and control patients and was investigated by applying the next-generation technology RNA-Seq.
Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
Walter Reinisch, MD, Krisztina Gecse, MD, Jonas Halfvarson, PhD, Peter M Irving, MA, MD, MRCP, J?rgen Jahnsen, MD, PhD ...
doi : 10.1093/ibd/izaa078
Inflammatory Bowel Diseases, Volume 27, Issue 1, January 2021, Pages 106–122
The introduction of tumor necrosis factor (TNF) inhibitors has significantly changed the treatment landscape in Crohn’s disease (CD). The overall therapeutic achievements with TNF inhibitors such as infliximab, adalimumab, and certolizumab pegol paved the way to push the boundaries of treatment goals beyond symptomatic relief and toward cessation of objective signs of inflammation, including endoscopic remission. Even though these agents are widely used for the treatment of moderate to severe CD, heterogeneity still exists in translating evidence-based guidelines on the use of anti-TNF agents into actual treatment algorithms in CD.
Optimizing Immunization Strategies in Patients with IBD
Freddy Caldera, DO, MS, Dana Ley, MD, Mary S Hayney, PharmD, MPH, Francis A Farraye, MD, MSc
doi : 10.1093/ibd/izaa055
Inflammatory Bowel Diseases, Volume 27, Issue 1, January 2021, Pages 123–133
Recent advances in the treatment of inflammatory bowel disease (IBD) include the use of immune modifiers and monoclonal antibodies, such as tumor necrosis factor (TNF) alpha inhibitors, anti-integrin agents, janus kinase inhibitors, and interleukin-12/23 inhibitors. These agents achieve higher rates of clinical remission and mucosal healing than conventional therapy. However, these therapies increase the risk of infections, including some vaccine-preventable diseases. Infections are one of the most common adverse event of immunosuppressive therapy. Thus, providers should optimize immunization strategies to reduce the risk of vaccine-preventable infections in patients with IBD. There are several newly licensed vaccines recommended for adults by the US Advisory Committee on Immunization Practices. This review will focus on how gastroenterology providers can implement the adult immunization schedule approved by ACIP for patients with IBD.
The Role of Citrullination in Inflammatory Bowel Disease: A Neglected Player in Triggering Inflammation and Fibrosis?
Gabriele Dragoni, MD, Gert De Hertogh, MD, PhD, Séverine Vermeire, MD, PhD
doi : 10.1093/ibd/izaa095
Inflammatory Bowel Diseases, Volume 27, Issue 1, January 2021, Pages 134–144
Citrullination is a posttranslational modification of proteins mediated by a specific family of enzymes called peptidylarginine deiminases (PAD). Dysregulation of these enzymes is involved in the etiology of various diseases, from cancer to autoimmune disorders.
Evaluation of Crohn’s Disease Activity: Development of an Ultrasound Score in a Multicenter Study
Tom?s Ripollés, MD, PhD, Joaqu?n Poza, MD, Cristina Suarez Ferrer, MD, PhD, Mar?a J Mart?nez-Pérez, MD, PhD, Ana Mart?n-Alg?bez, MD ...
doi : 10.1093/ibd/izaa134
Inflammatory Bowel Diseases, Volume 27, Issue 1, January 2021, Pages 145–154
Our goal in this multicentric prospective study was 2-fold: first, to test the diagnostic accuracy of ultrasound, color Doppler imaging (CDI), and contrast-enhanced ultrasound (CEUS) in identifying disease activity in patients with Crohn’s disease (CD) compared with endoscopy as the reference standard; and, second, to construct a sonographic score that allows disease activity to be detected.
An Unexpected Cause of Headache and Splenic Lesions During Anti-TNF Therapy in Crohn Disease
Raphael José da Silva, MD, Tarsila Campanha da Rocha Ribeiro, PhD, Liliana Andrade Chebli, PhD, Julio Maria Fonseca Chebli, PhD
doi : 10.1093/ibd/izaa226
Inflammatory Bowel Diseases, Volume 27, Issue 1, January 2021, Pages e1–e2
Improvement in Ulcerative Colitis by Administration of Benralizumab for Comorbid Refractory Bronchial Asthma: A Novel Clinical Observation
Ken Sugimoto, MD, PhD, Shoya Fujita, MD, Takahiro Miyazu, MD, Natsuki Ishida, MD, Shinya Tani, MD, PhD ...
doi : 10.1093/ibd/izaa225
Inflammatory Bowel Diseases, Volume 27, Issue 1, January 2021, Pages e3–e4
Response to “Histopathological Mimics of Inflammatory Bowel Disease”
Akira Hokama, MD, PhD, Hidenao Omija, MD, Kazuto Kishimoto, MD, PhD, Tatsuya Kinjo, MD, PhD, Tetsu Kinjo, MD, PhD ...
doi : 10.1093/ibd/izaa222
Inflammatory Bowel Diseases, Volume 27, Issue 1, January 2021, Pages e5–e6
Infliximab-induced Liver Injury: A Common Link Between Crohn’s Disease and Acute Liver Injury
Daniel D Penrice, MD, Amrit K Kamboj, MD, Douglas A Simonetto, MD
doi : 10.1093/ibd/izaa248
Inflammatory Bowel Diseases, Volume 27, Issue 1, January 2021, Pages e7–e8
Erratum to: Optimizing Immunization Strategies in Patients with IBD
Freddy Caldera, DO, MS, Dana Ley, MD, Mary S Hayney, PharmD, MPH, Francis A Farraye, MD, MSc
doi : 10.1093/ibd/izaa150
Inflammatory Bowel Diseases, Volume 27, Issue 1, January 2021, Page e9
